CEACAM1 based cancer therapy and diagnosis
US9795696B2 · kind B2 · utility
2Cited by
3References
2Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 9, 2006 |
| Grant date | Oct 24, 2017 |
| Priority date | — |
| Expiry date | Jun 9, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for detecting CEACAM1 expression in a cancer patient. In particular, methods according to the present invention include contacting a biological sample having Tumor Infiltrating Lymphocytes expressing CEACAM1 with an anti-CEACAM1 antibody labeled with a detectable moiety.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.